Cargando…

Sex-related differences in clinical outcomes and quality of life after transcatheter aortic valve implantation for severe aortic stenosis

INTRODUCTION: There are inconsistent data on the sex-related differences in clinical outcomes and quality of life (QoL) after transcatheter aortic valve implantation (TAVI). AIM: We sought to investigate sex-related differences in procedural, clinical and QoL outcomes of TAVI. MATERIAL AND METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Bagienski, Maciej, Tokarek, Tomasz, Wiktorowicz, Agata, Dziewierz, Artur, Rzeszutko, Lukasz, Sorysz, Danuta, Kleczynski, Pawel, Dudek, Dariusz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5644042/
https://www.ncbi.nlm.nih.gov/pubmed/29056996
http://dx.doi.org/10.5114/aic.2017.70195
Descripción
Sumario:INTRODUCTION: There are inconsistent data on the sex-related differences in clinical outcomes and quality of life (QoL) after transcatheter aortic valve implantation (TAVI). AIM: We sought to investigate sex-related differences in procedural, clinical and QoL outcomes of TAVI. MATERIAL AND METHODS: A total of 101 consecutive patients undergoing TAVI were enrolled. Patients were stratified by gender. Baseline characteristics, procedural and long-term clinical outcomes as well as frailty and QoL indices (EQ-5D-3L questionnaire) were compared between women and men. RESULTS: Women represented 60.4% of the study population. Periprocedural risk measured with the Logistic EuroSCORE and STS scale was similar for women and men. There were no differences in 30-day or 12-month all-cause mortality between groups (women vs. men: 9.8% vs. 12.5%; age-adjusted odds ratio (OR) (95% CI): 1.38 (0.39–4.94); 13.1% vs. 25.0%; age-adjusted OR (95% CI): 2.51 (0.87–7.25)). Men were at higher risk of new onset atrial fibrillation at follow-up (1.6% vs. 17.5%; age-adjusted OR (95% CI): 14.61 (1.68–127.37)). In multivariable Cox regression analysis, a history of stroke/transient ischemic attack (TIA) (hazard ratio (HR)) (95% CI): 3.93 (1.39–11.07) and blood transfusion (HR (95% CI): 2.84 (1.06–7.63)) were identified as independent factors affecting 12-month mortality. No differences in QoL parameters were noted. CONCLUSIONS: The TAVI can be considered as an effective and safe treatment in high-risk patients with severe aortic stenosis, regardless of gender.